Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Investing.com -- Shares of Swedish Orphan Biovitrum (STO:SOBI) fell by 4% today after the FDA approved Merck (NSE:PROR)’s respiratory syncytial virus (RSV) vaccine Enflonsia (clesrovimab), which will ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...